Do Innocent Errors Cause Most Retractions?

Contrary to previous studies, a new publication finds that most retractions from scholarly literature are not due to misconduct.

Written byBeth Marie Mole
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

Wikimedia, VmenkovIn a sweeping study that examined nearly 4,500 papers retracted from scholarly literature between 1928 and 2011, researchers found that most retractions were not a result of misconduct, and fewer than half were due to questionable data or interpretations. Instead, the study suggested, many retractions are a consequence of publishing misconduct or errors, such as plagiarism, duplicate publication, authorship issues, and unspecified copyright issues.

The results, published last week (October 24) in PLOS ONE, were based on information collected from retraction notices, however, critics say such notices may not always be accurate.

It’s a “methodological weakness,” microbiologist Ferric Fang of the University of Washington told Retraction Watch. “The information given in retraction notices was taken at face value,” said Fang, who led a similar study last month that found that most retractions were, in fact, due to misconduct and that many retractions notices were incomplete. Because “no attempt was made to independently verify the accuracy of the statements made in the notices,” he added, the new study’s findings—that 47 percent of paper retractions were due to publishing misconduct or errors, while only 20 percent were due to research misconduct ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies